Loading clinical trials...

Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection

NCT01197027•HIV Prevention Trials Network

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the acceptability and feasibility of an enhanced, individual-level counseling intervention for individuals in the acute and early phase of HIV infection aimed at reducing risk behaviors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•* Men and women aged ≥ 18 years at the time of screening.
•* Able and willing to provide adequate information for locator purposes.
•* Hemoglobin \> 10.0 g/dL.
•* Willing to receive HIV test results.
•* Not intending to relocate out of the area for the duration of study participation and does not have a job or other obligations that may require long absences from the area.
•* Has acute HIV infection. (See Section 2.3 for definition).

Exclusion Criteria

•Any prior or current use of antiretroviral therapy (ART). This does not apply to individuals screening for Group 1A. ART use for the prevention of perinatal transmission may be waived after prior consultation with the protocol team.
•* Previous or current participation in a HIV vaccine study. HPTN 062 Version 3.0 Final 03 August 2010
•* Any condition that, in the opinion of the Investigator of Record, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Locations (1)

Kamuzu Central Hospital

Lilongwe, Malawi

Key Dates

Start Date

February 1, 2010

Primary Completion Date

March 1, 2012

Completion Date

April 1, 2012

Last Updated

August 26, 2022

Enrollment

ACTUAL participants

Conditions

Acute HIV Infection

Interventions

Standard counseling

BEHAVIORAL

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

NCT00855413

Acute HIV InfectionHIV Infections

View study

COMPLETEDPHASE4

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

NCT00924898

Acute HIV InfectionHIV Infections

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 26, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection

Inclusion Criteria

Exclusion Criteria

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection